PD-1/PD-L1信号通路及相关抗体在宫颈癌免疫治疗中的应用

PD-1/PD-L1 signaling pathway and the application of its antibody in cervical cancer immunotherapy

程序性死亡蛋白1(PD-1)是T细胞上主要存在的一种抑制性受体,其与程序性死亡配体1(PD-L1)相互作用,可抑制T细胞增殖、活化和细胞因子的分泌。在肿瘤进展中,PD-1/PD-L1信号通路能够抑制T细胞的免疫反应而促进肿瘤免疫逃逸的发生。PD-1及PD-L1作为一种免疫应答的关键调控蛋白,与宫颈癌的发生发展及预后密切相关,PD-1及PD-L1抗体的深入研究将为治疗宫颈癌提供新的分子靶标。本文就PD-1/PD-L1生物学结构功能、在肿瘤的发生发展中的作用及其抗体在宫颈癌免疫治疗中的应用前景作一简要综述。

Programmed cell death protein 1（PD-1） is an inhibitory receptor present on T cells, which interacts with programmed death ligand 1（PD-L1） to inhibit the proliferation, activation and secretion of cytokines. In tumor progression, PD-1/PD-L1 signaling pathway can inhibit the immune response of T cells and promote the occurrence of tumor immune escape. PD-1 and PD-L1 as a key protein in the regulation of immune response, which is closely related with the occurrence, development and prognosis of cervical cancer, and further study of PD-1 and PD-L1 antibodies will provide new molecular targets for the treatment of cervical cancer. In this paper, we will review the biological structure and function of PD-1/PD-L1 and its role in the genesis and development of tumor and the prospect of its application in the treatment of cervical cancer.